Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
<p>Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell line. C. Chromosomal distribution of CNVs D. Repres...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Andere auteurs: | , , , , , , , , , , , , , , , , , |
| Gepubliceerd in: |
2025
|
| Onderwerpen: | |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
| _version_ | 1849927637256896512 |
|---|---|
| author | Michael Kilian (16697663) |
| author2 | Mirco Friedrich (3721555) Khwab Sanghvi (16697666) Edward Green (3822586) Stefan Pusch (14934437) Daisuke Kawauchi (15115187) Martin Löwer (133159) Jana K. Sonner (16697669) Christopher Krämer (16697672) Julia Zaman (16697675) Stefanie Jung (554730) Michael O. Breckwoldt (16697678) Gerald Willimsky (16697681) Stefan B. Eichmüller (16697684) Andreas von Deimling (15037904) Wolfgang Wick (15018168) Felix Sahm (15097382) Michael Platten (15018165) Lukas Bunse (16697687) |
| author2_role | author author author author author author author author author author author author author author author author author author |
| author_facet | Michael Kilian (16697663) Mirco Friedrich (3721555) Khwab Sanghvi (16697666) Edward Green (3822586) Stefan Pusch (14934437) Daisuke Kawauchi (15115187) Martin Löwer (133159) Jana K. Sonner (16697669) Christopher Krämer (16697672) Julia Zaman (16697675) Stefanie Jung (554730) Michael O. Breckwoldt (16697678) Gerald Willimsky (16697681) Stefan B. Eichmüller (16697684) Andreas von Deimling (15037904) Wolfgang Wick (15018168) Felix Sahm (15097382) Michael Platten (15018165) Lukas Bunse (16697687) |
| author_role | author |
| dc.creator.none.fl_str_mv | Michael Kilian (16697663) Mirco Friedrich (3721555) Khwab Sanghvi (16697666) Edward Green (3822586) Stefan Pusch (14934437) Daisuke Kawauchi (15115187) Martin Löwer (133159) Jana K. Sonner (16697669) Christopher Krämer (16697672) Julia Zaman (16697675) Stefanie Jung (554730) Michael O. Breckwoldt (16697678) Gerald Willimsky (16697681) Stefan B. Eichmüller (16697684) Andreas von Deimling (15037904) Wolfgang Wick (15018168) Felix Sahm (15097382) Michael Platten (15018165) Lukas Bunse (16697687) |
| dc.date.none.fl_str_mv | 2025-11-24T23:43:05Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30701933 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Figure_S2_from_T-cell_Receptor_Therapy_Targeting_Mutant_Capicua_Transcriptional_Repressor_in_Experimental_Gliomas/30701933 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy |
| dc.title.none.fl_str_mv | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell line. C. Chromosomal distribution of CNVs D. Representative immunofluorescence image of A2.DR1 glioma orthotopically injected into the brain of adult A2.DR1 mice, 20 days after injection. E. Relative expression of Cic in wild-type and CicR215W overexpressing A2.DR1 glioma cells as determined by RT-qPCR. F: Immunoblot depicting overexpression of the Cic protein in the CicR215W transfected cell line compared to the parental line (WT).</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_9a17bc8b389a1606bc3b97a3b9feeaea |
| identifier_str_mv | 10.1158/1078-0432.30701933 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30701933 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental GliomasMichael Kilian (16697663)Mirco Friedrich (3721555)Khwab Sanghvi (16697666)Edward Green (3822586)Stefan Pusch (14934437)Daisuke Kawauchi (15115187)Martin Löwer (133159)Jana K. Sonner (16697669)Christopher Krämer (16697672)Julia Zaman (16697675)Stefanie Jung (554730)Michael O. Breckwoldt (16697678)Gerald Willimsky (16697681)Stefan B. Eichmüller (16697684)Andreas von Deimling (15037904)Wolfgang Wick (15018168)Felix Sahm (15097382)Michael Platten (15018165)Lukas Bunse (16697687)CancerImmuno-oncologyCNS CancersGliomas, GlioblastomasImmunologyTumor antigens/neoantigensImmunotherapyCellular immunotherapy<p>Supplementary Figure 2: Molecular features of A2.DR1 MHC-humanized gliomas. A. Verification of the CRISPR-Cas9-mediated functional KO of p53 and Nf1 in the A2.DR1 glioma cell line. B. Copy number variations (CNVs) in the A2.DR1 glioma cell line. C. Chromosomal distribution of CNVs D. Representative immunofluorescence image of A2.DR1 glioma orthotopically injected into the brain of adult A2.DR1 mice, 20 days after injection. E. Relative expression of Cic in wild-type and CicR215W overexpressing A2.DR1 glioma cells as determined by RT-qPCR. F: Immunoblot depicting overexpression of the Cic protein in the CicR215W transfected cell line compared to the parental line (WT).</p>2025-11-24T23:43:05ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/1078-0432.30701933https://figshare.com/articles/figure/Figure_S2_from_T-cell_Receptor_Therapy_Targeting_Mutant_Capicua_Transcriptional_Repressor_in_Experimental_Gliomas/30701933CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307019332025-11-24T23:43:05Z |
| spellingShingle | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas Michael Kilian (16697663) Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy |
| status_str | publishedVersion |
| title | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| title_full | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| title_fullStr | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| title_full_unstemmed | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| title_short | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| title_sort | Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas |
| topic | Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy |